Compounds > n,n-diacetylcystine
Page last updated: 2024-12-11

n,n-diacetylcystine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N,N-diacetylcystine: RN given refers to L-isomer; DiNAC is the lysine salt; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6995101
CHEMBL ID4303405
SCHEMBL ID308082
MeSH IDM0159001

Synonyms (34)

Synonym
5545-17-5
n,n'-diacetylcystine
n,n'-diacetyl-l-cystine
nsc 203780
einecs 226-911-5
n,n-diacetylcystine
l-cystine, n,n'-diacetyl-
5h6na7ju5e ,
unii-5h6na7ju5e
AM20100361
(ac-cys-oh)2
n,n'-diacetyl-l-cystine, 90%
SCHEMBL308082
c10h16n2o6s2
FD21227
mfcd00152053
AKOS027250793
CCG-257560
CCG-257528
Z2153972216
n,n'-diacetyl-l-cystine; acetylcysteine imp. c (ep); acetylcysteine impurity c
acetylcysteine impurity c [ep impurity]
YTPQSLLEROSACP-YUMQZZPRSA-N
CS-0083231
HY-114348
AS-49003
(ac-cys-oh)2 (disulfide bond)
(2r,2'r)-3,3'-disulfanediylbis(2-acetamidopropanoic acid)
d-7193
CHEMBL4303405
A899770
acetylcysteine impurity c
(2r)-3-{[(2r)-2-carboxy-2-acetamidoethyl]disulfanyl}-2-acetamidopropanoic acid
EN300-304165
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's7 (63.64)29.6817
2010's0 (0.00)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.70 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (81.82%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
probucol
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).. probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.		2.4120dithioketal;
polyphenol		anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug
dinitrofluorobenzene
Dinitrofluorobenzene: Irritants and reagents for labeling terminal amino acid groups.. 1-fluoro-2,4-dinitrobenzene : The organofluorine compound that is benzene with a fluoro substituent at the 1-position and two nitro substituents in the 2- and 4-positions.		210C-nitro compound;
organofluorine compound		agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		9.551acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		210fluorescein isothiocyanate
mdl 29311
MDL 29311: structure given in first source		2.0110
oxazolone
Oxazolone: Immunologic adjuvant and sensitizing agent.		2.4120
cystine
[no description available]		11.3111
bilirubin
[no description available]		2.0210biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		7.4220cysteiniumfundamental metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Thrombotic Stroke
[description not available]		02.3110
Blood Clot
[description not available]		02.3110
Thrombosis
Formation and development of a thrombus or blood clot in the blood vessel.		02.3110
Delayed Hypersensitivity
[description not available]		03.3320
Arteriosclerosis
Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.		03.8440
Acute Hepatic Failure
[description not available]		02.0210
Liver Failure, Acute
A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.		02.0210
Elevated Cholesterol
[description not available]		03.4311
Active Hyperemia
[description not available]		03.4311
Hypercholesterolemia
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.		03.4311
Hyperemia
The presence of an increased amount of blood in a body part or an organ leading to congestion or engorgement of blood vessels. Hyperemia can be due to increase of blood flow into the area (active or arterial), or due to obstruction of outflow of blood from the area (passive or venous).		03.4311
Atherogenesis
[description not available]		02.0310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0310
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.0310
Contact Dermatitis
[description not available]		02.730
Granulomas
[description not available]		0210
Dermatitis, Contact
A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.		02.730
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		0210